Comments on: The Vytorin Data At The ACC: No Smoking Gun? http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/ News, Comment and Conversation Fri, 10 Feb 2012 20:17:07 +0000 http://wordpress.org/?v=2.6.2 By: Doc http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235921 Doc Sun, 30 Mar 2008 16:31:22 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235921 HC, I take statins and other lipid drugs as well, but the pleitrophy data is virtually all in vitro and in rat-o. HC,
I take statins and other lipid drugs as well, but the pleitrophy data is virtually all in vitro and in rat-o.

]]> By: HorusCat http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235848 HorusCat Sun, 30 Mar 2008 15:43:03 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235848 Doc, Maybe so, but with my family history and lipid profile, I am wishing away. Doc,

Maybe so, but with my family history and lipid profile, I am wishing away.

]]> By: Doc http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235810 Doc Sun, 30 Mar 2008 15:19:38 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-235810 Statin pleiotropy is an unproven wish. Statin pleiotropy is an unproven wish.

]]> By: HorusCat http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-234408 HorusCat Sat, 29 Mar 2008 21:35:01 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-234408 MKM, You're great. Poor rats. MKM,

You’re great. Poor rats.

]]> By: MKM http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-233665 MKM Sat, 29 Mar 2008 13:10:43 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-233665 Here's another interesting study: Birnbaum et al., Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat, Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 1, 72-79 (2008). Statins reduce infarct size by upregulating nitric oxide synthases and PGI2 production. In this article, the infarct size-limiting effect of low-dose simvastatin + ezetimibe, ezetimibe, and high-dose statins were compared. Rats received 3-day water, atorvastatin (10 mg/kg/d), simvastatin (10 mg/kg/d), simvastatin (2 mg/kg/d), simvastatin (2 mg/kg/d) + ezetimibe (1 mg/kg/d), or ezetimibe. Rats underwent 30-minute coronary artery occlusion and 4-hour reperfusion. Atorvastatin and simvastatin 10 reduced infarct size, whereas simvastatin 2, ezetimibe, and simvastatin 2 + ezetimibe had no effect. Atorvastatin and simvastatin 10 increased nitric oxide synthases activity, whereas simvastatin-2, ezetimibe, and simvastatin-2 + ezetimibe had only a small effect. Atorvastatin and simvastatin 10 significantly increased myocardial 6-ketoprostaglandin F1 levels, whereas simvastatin 2, ezetimibe, and simvastatin 2 + ezetimibe had no effect. High-dose statin is required to decrease infarct size, upregulate myocardial nitric oxide synthases activities, and increase 6-keto prostaglandin F1 levels. Combination of ezetimibe and low-dose statin is ineffective in modulating myocardial biochemical changes associated with cardioprotection. Here’s another interesting study:

Birnbaum et al., Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat, Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 1, 72-79 (2008).

Statins reduce infarct size by upregulating nitric oxide synthases and PGI2 production. In this article, the infarct size-limiting effect of low-dose simvastatin + ezetimibe, ezetimibe, and high-dose statins were compared. Rats received 3-day water, atorvastatin (10 mg/kg/d), simvastatin (10 mg/kg/d), simvastatin (2 mg/kg/d), simvastatin (2 mg/kg/d) + ezetimibe (1 mg/kg/d), or ezetimibe. Rats underwent 30-minute coronary artery occlusion and 4-hour reperfusion. Atorvastatin and simvastatin 10 reduced infarct size, whereas simvastatin 2, ezetimibe, and simvastatin 2 + ezetimibe had no effect. Atorvastatin and simvastatin 10 increased nitric oxide synthases activity, whereas simvastatin-2, ezetimibe, and simvastatin-2 + ezetimibe had only a small effect. Atorvastatin and simvastatin 10 significantly increased myocardial 6-ketoprostaglandin F1 levels, whereas simvastatin 2, ezetimibe, and simvastatin 2 + ezetimibe had no effect. High-dose statin is required to decrease infarct size, upregulate myocardial nitric oxide synthases activities, and increase 6-keto prostaglandin F1 levels. Combination of ezetimibe and low-dose statin is ineffective in modulating myocardial biochemical changes associated with cardioprotection.

]]> By: HorusCat http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232193 HorusCat Fri, 28 Mar 2008 18:56:05 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232193 Jack2 is right about Insider being right about SP2. (I couldn't resist; but they are right.) Thanks MKM. Jack2 is right about Insider being right about SP2. (I couldn’t resist; but they are right.)

Thanks MKM.

]]> By: Jack2 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232063 Jack2 Fri, 28 Mar 2008 17:16:05 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232063 Insider is right about SP2. Insider is right about SP2.

]]> By: MKM http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232060 MKM Fri, 28 Mar 2008 17:13:19 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232060 Is "Der Waarheid" Afrikans? What does it mean? Thanks Marilyn Is “Der Waarheid” Afrikans? What does it mean?

Thanks Marilyn

]]> By: Der Waarheid http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232016 Der Waarheid Fri, 28 Mar 2008 16:37:08 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-232016 I have repeatedly stated that it is not the data, it is the (attempted) manipulation of the data that is rotten. I think that MKMs citation of sim v ezet confirms the shortcomings of V/Z. Taken in context, this just makes the delay in ENHANCE even more of a money grab. As this cited data has a release date of 2005, one could hypothesize that knowing of this earlier trial result, FH and CC could expect similar results from ENHANCE and have since enriched many insiders at the expense of patients, insurers, the US Govt, shareholders and employees. Is this idea a stetch? You decide. I have repeatedly stated that it is not the data, it is the (attempted) manipulation of the data that is rotten. I think that MKMs citation of sim v ezet confirms the shortcomings of V/Z. Taken in context, this just makes the delay in ENHANCE even more of a money grab. As this cited data has a release date of 2005, one could hypothesize that knowing of this earlier trial result, FH and CC could expect similar results from ENHANCE and have since enriched many insiders at the expense of patients, insurers, the US Govt, shareholders and employees. Is this idea a stetch? You decide.

]]> By: Insider http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-231970 Insider Fri, 28 Mar 2008 16:09:20 +0000 http://www.pharmalot.com/2008/03/the-vytorin-data-at-the-acc-no-smoking-gun/#comment-231970 SP 2 is right. SP 2 is right.

]]>